We are live on ! Find out more
ITCI

Intra-Cellular Therapies Inc.
ITCI

Delisted

ITCI was delisted on the 1st of April, 2025.

Back to rankings

126 hedge funds and large institutions have $298M invested in Intra-Cellular Therapies Inc. in 2019 Q3 according to their latest regulatory filings, with 26 funds opening new positions, 42 increasing their positions, 35 reducing their positions, and 25 closing their positions.

New
Increased
Maintained
Reduced
Closed

20% more repeat investments, than reductions

Existing positions increased: 42 | Existing positions reduced: 35

4% more first-time investments, than exits

New positions opened: 26 | Existing positions closed: 25

0% more funds holding

Funds holding: 126 → 126 (0)

40% less capital invested

Capital invested by funds: $498M → $298M (-$200M)

41% less call options, than puts

Call options by funds: $15.4M | Put options by funds: $26.2M

Holders
126
Holders Change
–
Holders Change %
0%
% of All Funds
2.76%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
26
Increased
42
Reduced
35
Closed
25
Calls
$15.4M
Puts
$26.2M
Net Calls
-$10.8M
Net Calls Change
-$40.6M

Top Buyers

Rank Fund Capital Flow
1
WA
Wasatch Advisors
Utah
+$16M
2
Millennium Management
Millennium Management
New York
+$10.6M
3
ClearBridge Investments
ClearBridge Investments
New York
+$7.53M
4
Point72 Asset Management
Point72 Asset Management
Connecticut
+$5.37M
5
CS
Candriam SCA
Luxembourg
+$3.84M

Top Sellers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
-$20.5M
2
Franklin Resources
Franklin Resources
California
-$7.98M
3
FMBTD
First Midwest Bank Trust Division
Illinois
-$7.79M
4
CCI
Columbus Circle Investors
-$6.93M
5
N
Nuveen
North Carolina
-$3.61M
Name Holding Trade Value Shares
Change 		Change in
Stake
Two Sigma Investments
26
Two Sigma Investments
New York
$1.49M -$265K -27,673 -12%
Jacobs Levy Equity Management
27
Jacobs Levy Equity Management
New Jersey
$1.48M +$779K +81,243 +70%
Bank of New York Mellon
28
Bank of New York Mellon
New York
$1.42M -$146K -15,226 -7%
Deutsche Bank
29
Deutsche Bank
Germany
$1.4M -$542K -56,565 -23%
OM
30
Opaleye Management
Massachusetts
$1.27M +$1.63M +170,000 New
Squarepoint
31
Squarepoint
New York
$1.1M +$899K +93,712 +175%
PAMU
32
Pictet Asset Management (UK)
United Kingdom
$1.09M +$81.5K +8,500 +6%
ARTA
33
A.R.T. Advisors
New York
$1.07M +$1.06M +110,700 +333%
Two Sigma Advisers
34
Two Sigma Advisers
New York
$1.04M -$251K -26,200 -16%
PP
35
PDT Partners
New York
$969K +$811K +84,537 +187%
JG
36
Jefferies Group
New York
$899K +$1.09M +113,387 +1,617%
Verition Fund Management
37
Verition Fund Management
Connecticut
$882K +$1.13M +118,091 New
Goldman Sachs
38
Goldman Sachs
New York
$857K -$167K -17,431 -13%
Ohio Public Employees Retirement System (OPERS)
39
Ohio Public Employees Retirement System (OPERS)
Ohio
$842K +$397K +41,393 +58%
PVI
40
Pura Vida Investments
New York
$815K +$1.05M +109,130 New
Bank of America
41
Bank of America
North Carolina
$795K +$548K +57,149 +116%
Macquarie Group
42
Macquarie Group
Australia
$747K -$73K -7,616 -7%
RJA
43
Raymond James & Associates
Florida
$676K +$58.4K +6,095 +7%
Swiss National Bank
44
Swiss National Bank
Switzerland
$649K – – –
AllianceBernstein
45
AllianceBernstein
Tennessee
$599K +$97.8K +10,200 +15%
T. Rowe Price Associates
46
T. Rowe Price Associates
Maryland
$542K -$2.71M -282,922 -80%
California Public Employees Retirement System
47
California Public Employees Retirement System
California
$524K +$105K +11,000 +19%
California State Teachers Retirement System (CalSTRS)
48
California State Teachers Retirement System (CalSTRS)
California
$512K – – –
RhumbLine Advisers
49
RhumbLine Advisers
Massachusetts
$503K +$35.9K +3,740 +6%
DekaBank Deutsche Girozentrale
50
DekaBank Deutsche Girozentrale
Germany
$493K -$630K -65,700 -50%
1
2
3 4 5

ITCI Hedge Fund Activity: Q3 2019 in Review

126 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Intra-Cellular Therapies Inc. (ITCI) for Q3 2019, worth a combined $298M — down 40% from $498M a quarter earlier.

Buyers outnumbered sellers: 26 funds opened new ITCI positions and 25 closed out — a net gain of 1 holder — while 42 added to existing stakes and 35 trimmed.

The largest buyer was Wasatch Advisors, adding an estimated $16M. The largest seller was Fidelity Investments, cutting an estimated $20.5M.

  • 126 institutional investors held Intra-Cellular Therapies Inc. (ITCI) as of Q3 2019, unchanged from Q2 2019.
  • Funds reported $298M of Intra-Cellular Therapies Inc. stock for Q3 2019, down 40% quarter-over-quarter.
  • 26 funds opened new Intra-Cellular Therapies Inc. positions in Q3 2019 and 25 closed out, a net change of +1 holder.
  • The largest Intra-Cellular Therapies Inc. buyer in Q3 2019 was Wasatch Advisors, an estimated $16M added.
  • The largest Intra-Cellular Therapies Inc. seller in Q3 2019 was Fidelity Investments, an estimated $20.5M sold.

Based on aggregated 13F filings for Q3 2019.